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Background: We report here on 14438 Streptococcus pneumoniae and 14770 Haemophilus influenzae isolates
collected from 560 centres globally between 2004 and 2012 as a part of the Tigecycline Evaluation and Surveillance
Trial (T.E.S.T.).
Methods: MIC testing was performed using broth microdilution methods as described by the Clinical and Laboratory
Standards Institute (CLSI) using CLSI-approved breakpoints; US Food and Drug Administration breakpoints were used
for tigecycline as CLSI breakpoints are not available.
Results: At least 99% of S. pneumoniae isolates globally were susceptible to levofloxacin, linezolid, tigecycline or
vancomycin. Penicillin resistance was observed among 14.8% of S. pneumoniae and was highest in Asia/Pacific Rim
(30.1%) and Africa (27.6%); 23.4% of S. pneumoniae isolates were penicillin-intermediate, which were most common in
Africa (37.6%). Minocycline susceptibility among S. pneumoniae decreased by 20% between 2004-2008 and 2009-2012.
High (>98.5%) susceptibility was reported among H. influenzae to all antimicrobial agents on the T.E.S.T. panel excluding
ampicillin, to which only 78.3% were susceptible. β-lactamase production was observed among 20.2% of H. influenzae
isolates; 1.5% of isolates were β-lactamase negative, ampicillin-resistant.
Conclusions: S. pneumoniae remained highly susceptible to levofloxacin, linezolid, tigecycline and vancomycin while
H. influenzae was susceptible to most antimicrobial agents in the testing panel (excluding ampicillin).
Keywords: Antimicrobial susceptibility, Streptococcus pneumoniae, Haemophilus influenzae, TigecyclineBackground
Streptococcus pneumoniae and Haemophilus influenzae
are among the most common causes of pneumonia world-
wide [1,2]. According to the most recent guidelines for the
treatment of community-acquired pneumonia (CAP) pub-
lished by the Infectious Diseases Society of America and* Correspondence: viktorija.tomic@klinika-golnik.si
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article, unless otherwise stated.American Thoracic Society [3], the recommended empiric
therapy for inpatient CAP includes a β-lactam (cefotax-
ime, ceftriaxone or ampicillin-sulbactam) plus either a re-
spiratory fluoroquinolone or azithromycin for intensive
care unit (ICU) patients or a respiratory fluoroquinolone
or β-lactam plus a macrolide for non-ICU patients.
European guidelines are also available [4], while several
European countries have established their own policies
regarding the treatment of CAP including the UK [5],
Sweden [6] and the Netherlands [7]. These guidelinesCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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when bacteriology is similar between countries [8].
The Tigecycline Evaluation and Surveillance Trial
(T.E.S.T.) is a global surveillance study which has been
ongoing since 2004. This study was designed to monitor
the longitudinal activity of a broad panel of comparator
agents, including the glycylcycline antimicrobial tige-
cycline, against a collection of clinically important pa-
thogens. Tigecycline possesses potent in vitro activity
against those pathogens most often responsible for
community-acquired pneumonia [9]. In 2009, the US
Food and Drug Administration approved tigecycline for
the treatment of community-acquired bacterial pneu-
monia (CABP) caused by Streptococcus pneumoniae
(penicillin-susceptible isolates), including cases with con-
current bacteremia, Haemophilus influenzae (β-lactamase
negative isolates), and Legionella pneumophila in the USA
[10], based in part on results from a pair of Phase III cli-
nical trials comparing the efficacy of tigecycline and levo-
floxacin in hospitalized patients with CABP [11]. In the
current study, we examine susceptibility trends among
isolates of S. pneumoniae and H. influenzae collected from
Africa, the Asia/Pacific Rim, Europe, Latin America, the
Middle East and North America between 2004 and 2012.
This report updates S. pneumoniae and H. influenzae
data previously reported from T.E.S.T. between 2004 and
2008 [12]. In that report, a total of 6785 S. pneumoniae
and 6642H. influenzae were analyzed. Penicillin resistance
among S. pneumoniae ranged from 9.3% in Europe to
25.1% in the Asia-Pacific Rim and β-lactamase producing
H. influenzae ranged from 8.7% in South Africa to 26.8%
in the Asia-Pacific Rim. The MIC90s for tigecycline against
S. pneumoniae and H. influenzae were ≤0.12 mg/L
and ≤2 mg/L, respectively. Data from that 2004-2008 re-
port are included in the dataset used in this report. This
report aims to provide an update to Darabi et al. [12],
comparing 2004-2008 data with data collected between
2009 and 2012.Table 1 Number of centres contributing S. pneumoniae or H.
Regiona 2004 2005 2006 2007
Africa 1 4 4 6
Asia/Pacific Rim 7 6 20 24
Europe 31 25 50 70
Latin America 4 13 22 24
Middle East 1 2 3 5
North America 70 110 99 92
Global 114 160 198 221
aAfrica = Mauritius, Morocco, South Africa, Tunisia; Asia/Pacific Rim = Australia, China
Taiwan, Thailand; Europe = Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denm
Norway, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden, Switz
Chile, Colombia, Guatemala, Honduras, Jamaica, Mexico, Panama, Venezuela; Middle
America = Canada, United States.
bTotal = the total number of unique centres contributing isolates between 2004 andMethods
Isolate collection
Between 2004 and 2012, a total of 560 centres globally
contributed isolates to the T.E.S.T. study in at least a
single study year (Table 1). All centres participating in
T.E.S.T. were required to contribute a minimum of
65 Gram-positive and 135 Gram-negative isolates per
study year; these were to include at least 15 isolates of
both S. pneumoniae and H. influenzae annually. North
America and Europe were the main contributors, with
221 and 196 centres participating in the two regions,
respectively.
All body sites were considered acceptable sources for
isolate collection; a maximum of 25% of isolates in any
year could be urinary in origin. Banked or stored isolates
were not accepted, nor were duplicate isolates from a
single patient. Isolates were collected from 13 different
body sites (Table 2); a small number of isolates were col-
lected from medical instruments. Isolates were included
into the study if they were considered a clinically rele-
vant causative organism and the probable causative
agent of the infection. Patient age, medical history or
gender were not considered relevant. Isolate identifica-
tion was carried out by contributing centres using rou-
tine local methodologies.
The central repository for all isolates was International
Health Management Associates (IHMA, Schaumburg,
IL, USA), who were responsible for organism transport
and collection, confirmation of isolate identification and
the management of a database including all isolate data.
Quality control testing was carried out daily using S.
pneumoniae ATCC 49619, H. influenzae ATCC 49247
and H. influenzae ATCC 49766. Approximately 10-15%
of isolates were randomly tested annually by IHMA to
verify isolate identity and MICs; MIC data were used
only if daily QC results were within acceptable ranges as
published by the Clinical and Laboratory Standards
Institute (CLSI) [13].influenzae isolates between 2004 and 2012
2008 2009 2010 2011 2012 Totalb
2 2 0 1 8 16
17 14 12 1 13 48
104 112 95 35 108 196
35 29 15 6 25 59
9 9 9 4 7 20
45 43 32 23 80 221
212 209 163 70 241 560
, Hong Kong, India, Malaysia, Pakistan, Philippines, Singapore, South Korea,
ark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania,
erland, The Netherlands, United Kingdom; Latin America = Argentina, Brazil,
East = Israel, Jordan, Kuwait, Lebanon, Oman, Saudi Arabia, Turkey; North
2012.
Table 2 Geographic distribution and culture source (>5%
of total) of S. pneumoniae and H. influenzae isolates
2004 - 2008 2009 - 2012 2004 - 2012
n % n % n %
S. pneumoniae n = 8864 n = 5574 n = 14438
Region
Africa 156 1.8 65 1.2 221 1.5
Asia/Pacific Rim 689 7.8 296 5.3 985 6.8
Europe 2786 31.4 2983 53.5 5769 40.0
Latin America 771 8.7 397 7.1 1168 8.1
Middle East 182 2.1 278 5.0 460 3.2
North America 4280 48.3 1555 27.9 5835 40.4
Culture source
Respiratory 4292 48.4 2583 46.3 6875 47.6
Cardiovascular 2614 29.5 1588 28.5 4202 29.1
HEENT 1255 14.2 861 15.4 2116 14.7
Bodily fluids 463 5.2 346 6.2 809 5.6
H. influenzae n = 8732 n = 6038 n = 14770
Region
Africa 157 1.8 61 1.0 218 1.5
Asia/Pacific Rim 688 7.9 302 5.0 990 6.7
Europe 3011 34.5 3311 54.8 6322 42.8
Latin America 747 8.6 410 6.8 1157 7.8
Middle East 210 2.4 281 4.7 491 3.3
North America 3919 44.9 1673 27.7 5592 37.9
Culture source
Respiratory 6340 72.6 4167 69.0 10507 71.1
HEENT 1562 17.9 1163 19.3 2725 18.4
Cardiovascular 439 5.0 363 6.0 802 5.4
Bodily fluids includes abscess/pus, abdominal, bile, cerebrospinal fluid,
pericardial, peritoneal, pleural, synovial and tissue; Cardiovascular includes
cardiovascular, blood, blood vessels and heart; HEENT includes head, ears,
eyes, nose and throat; Respiratory includes respiratory, bronchial brushing,
bronchials, bronchoalveolar lavage, endotracheal aspirate, lungs, sinuses,
sputum and trachea.
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All centres were responsible for minimum inhibitory
concentration (MIC) testing using broth microdilution
methods described by CLSI [14] using either MicroScan®
panels (Dade Microscan Inc., West Sacramento, CA,
USA) or Sensititre® plates (TREK Diagnostic Systems, East
Grinstead, UK). The T.E.S.T. test panel for S. pneumoniae
included the following antimicrobial agents: amoxicillin-
clavulanate, ampicillin, ceftriaxone, imipenem, levofloxacin,
linezolid, meropenem, minocycline, penicillin, piperacillin-
tazobactam, tigecycline and vancomycin. Azithromycin,
clarithromycin, clindamycin and erythromycin were added
to the T.E.S.T. panel for S. pneumoniae in 2008, with older
isolates tested retrospectively. H. influenzae MICs were
determined using a panel which included amikacin,amoxicillin-clavulanate, ampicillin, cefepime, ceftria-
xone, imipenem, levofloxacin, meropenem, minocycline,
piperacillin-tazobactam and tigecycline. In 2006, imipe-
nem testing with MicroScan® plates was replaced in the
T.E.S.T. panel with meropenem using Sensititre® plates
due to imipenem stability problems.
Antimicrobial susceptibility was determined using
CLSI-approved breakpoints [13] with the exception of
tigecycline, for which US Food and Drug Administration
(FDA)-approved breakpoints were used as CLSI break-
points are not available for tigecycline [15]. Penicillin oral
breakpoints (susceptible ≤0.06 mg/L, resistant ≥2 mg/L)
were used for S. pneumoniae in this study; penicillin-
intermediate S. pneumoniae (PISP) was defined as a peni-
cillin MIC between 0.12 and 1 mg/L.
The MIC results for 2004-2008 presented here do not
exactly match the results presented in Darabi et al. [12]
due to retesting of selected isolates from 2004-2008
through the intervening study period or the deletion of
untestable isolates from the T.E.S.T. database (most
often due to loss of culture viability).
Antimicrobial resistance determination
β-lactamase production among H. influenzae was deter-
mined at collecting centres using preferred local method-
ologies. The central lab, IHMA, retested all H. influenzae
if the ampicillin results did not agree with the β-lactamase
determination. The central laboratory (IHMA) uses
the cefinase test [15]. Only 15 β-lactamase-negative,
ampicillin-resistant (BLNAR) H. influenzae isolates
were collected globally during this study; therefore, we
have replicated the approach of Darabi et al. [12] here
and have included β-lactamase-negative, ampicillin-
intermediate (BLNAI) isolates as well. This resulted in a
total of 228 BLNAR isolates globally.
Statistical analysis
A comparison of rates of susceptibility between the two
time periods 2004–2008 and 2009–2012 was carried out
using the Fisher’s Exact Test. The upper and lower 95%
confidence intervals (CI) presented in this manuscript
relate to percentage susceptibility. The 95% CI for the
percentage susceptible presented in this manuscript were




In total, 14438 S. pneumoniae isolates were contributed
to T.E.S.T. between 2004 and 2012 (Table 2). North
America was the largest contributor of S. pneumoniae
isolates between 2004 and 2008 (48.3%) while Europe
contributed the most isolates between 2009 and 2012
(53.5%) (Table 2). The most common isolate sources for
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followed by cardiovascular (29.1%) (Table 2).
Globally, S. pneumoniae was highly susceptible to vanco-
mycin (100%), linezolid (>99.9%), tigecycline (99.9%), and
levofloxacin (>98.9%) (Additional file 1: Table S1). The glo-
bal susceptibility of S. pneumoniae to most other T.E.S.T.
panel agents decreased slightly, often by <1%, between
2004-2008 and 2009-2012. The largest change was ob-
served for minocycline: susceptibility to this agent de-
creased significantly (p < 0.0001) from 72.1% in 2004-2008
(95% CI 71.2–73.0) to 51.7% in 2009-2012 (95% CI 50.4–
53.0). This drop in minocycline susceptibility was observed
in all regions, ranging from 15.5% in Europe to 31.7% in
Latin America (Additional file 1: Table S1). Conversely,
global susceptibility to meropenem and penicillin in-
creased significantly (p < 0.0001) between 2004–2008 and
2009–2012; for meropenem from 79.5% (95% CI 78.4–
80.5) to 83.4% (95% CI 82.4–84.3) and for penicillin from
60.0% (95% CI 59.0–61.1) to 64.8% (95% CI 63.5–66.0).
Meropenem susceptibility increased in all regions, al-
though the change was only statistically significant in Eur-
ope (p < 0.01) where susceptibility increased from 84.9%
(95% CI 83.3–86.5) in 2004–2008 to 88.0% (95% CI 86.8–
89.2) in 2009–2012. Penicillin susceptibility increased in
Africa (11.7%), Asia/Pacific Rim (3.5%), Europe (0.9%) and
North America (6.0%) but decreased in Latin America
(7.2%) and the Middle East (3.2%). The change was only
statistically significant in North America (p < 0.0001)
where susceptibility increased from 57.3% (95% CI 55.8–
58.8) to 63.3% (95% CI 60.9–65.7).
Some notable regional changes in S. pneumoniae sus-
ceptibility were reported which did not impact largely
on global rates (Additional file 1: Table S1). In Asia/
Pacific Rim, decreases in susceptibility of between 8.3%
and 16.0% between 2004–2008 and 2009–2012 were seen
for amoxicillin-clavulanate (p < 0.001, 95% CI 86.9–91.6;
76.2-85.4), ceftriaxone (p < 0.0001, 95% CI 87.7–92.3; 72.9–
82.6), azithromycin (p < 0.01, 95% CI 44.6–53.0; 33.5–45.2),
clarithromycin (p < 0.01, 95% CI 44.8–53.1; 33.5–45.2),
erythromycin (p < 0.01, 95% CI 44.5–52.8; 33.2–44.8) and
clindamycin (p < 0.0001, 95% CI 61.1–69.0; 43.2–55.1). In
the Middle East, macrolide susceptibility decreased by ap-
proximately 10% although the decrease was not statistically
significant.
Macrolide susceptibility was strongly influenced by
penicillin non-susceptibility among S. pneumoniae.
PISP isolates were 17% less susceptible to macrolides
than all S. pneumoniae globally combined; susceptibility
was reduced by approximately 45% among penicillin-
resistant S. pneumoniae (PRSP) isolates (Additional
file 1: Table S1). Macrolide susceptibility among all
S. pneumoniae varied widely by region in this study,
ranging from 45% in Asia/Pacific Rim to 72%–73% in
Latin America; macrolide susceptibility among PRSPranged from 5% in Asia/Pacific Rim to 45% in Latin
America.
Ceftriaxone susceptibility among S. pneumoniae isolates
decreased in all regions between 2004–2008 and 2009–
2012, by 3.2% globally (p < 0.0001) from 96.3% (95% CI
95.9–96.7) to 93.1% (95% CI 92.4–93.7) and by as much
as 12.1% in the Asia/Pacific Rim [from 90.1% susceptible
(95% CI 87.7–92.3) to 78.0% (95% CI 72.9–82.6)]. The de-
crease in ceftriaxone susceptibility was considerably more
pronounced among PRSP isolates: susceptibility dropped
by ≥18.8% in 5 of the 6 regions globally and by as much as
35% in Latin America, decreasing from 80.0% (95% CI
71.1–87.2) to 45.0% (95% CI 32.1–58.4) (p < 0.0001), with
a global decrease in susceptibility of 21.2% observed bet-
ween 2004-2008 (78.1% susceptible, 95% CI 75.8–80.3)
and 2009-2012 (56.9% susceptible, 95% CI 53.4–60.4)
(p < 0.0001) (Additional file 1: Table S1).
Levofloxacin, linezolid, tigecycline and vancomycin
retained similar activity against PRSP isolates compared
with all S. pneumoniae isolates globally. All other anti-
microbial agents showed decreases in activity against
PRSP, as high as 45% among the macrolides and over
70% among the carbapenems (meropenem and imipe-
nem) (Additional file 1: Table S1). This was most no-
ticeable in Asia/Pacific Rim, where PRSP susceptibility
to the macrolides, ceftriaxone, clindamycin and minocy-
cline (5%, 56.4%, 28.4% and 9.5%, respectively) was much
lower than global levels (20-22%, 70.1%, 43.4% and
27.6%).
Regarding resistance phenotypes, 3374 (23.4%) were
PISP while 2132 (14.8%) were PRSP globally (Additional
file 1: Table S1, Table 3). Regionally, PISP levels were
highest in Africa (37.6%), Latin America (31.3%) and
Middle East (30.7%) during the complete study interval;
PISP levels increased by almost 6% in Latin America but
decreased by >18% in Africa, although these changes
were not statistically significant. The prevalence of PISP
decreased globally, from 25.0% (95% CI 24.1-25.9) in
2004-2008 to 20.8% (95% CI 19.7-21.9) in 2009-2012
(p < 0.0001) (Table 3). PRSP isolates were most prevalent
in Asia/Pacific Rim (30.1%) and Africa (27.6%) between
2004 and 2012; rates of PRSP increased in both of these
regions between 2004-08 and 2009-12 (>4% and >6%, re-
spectively) although the changes were not statistically
significant. The prevalence of PRSP was stable globally,
decreasing only slightly from 15.0% (95% CI 14.2-15.7)
in 2004-2008 to 14.4% (95% CI 13.5-15.4) in 2009-2012
(Table 3).
H. influenzae
A total of 14770 isolates of H. influenzae were contri-
buted between 2004 and 2012 as a part of the T.E.S.T.
study. North America was the largest contributor of
H. influenzae isolates over 2004-2008 (44.9%) while
Table 3 Rates of PISP and PRSP plus β-lactamase-positive H. influenzae and BLNAR, regionally and globally
PISP n (%) PRSP n (%) BL-Pos HI n (%) BLNARa n (%)
2004-08 2009-12 2004-12 2004-08 2009-12 2004-12 2004-08 2009-12 2004-12 2004-08 2009-12 2004-12
Africa 67/156 (42.9) 16/65 (24.6) 83/221 (37.6) 40/156 (25.6) 21/65 (32.3) 61/221 (27.6) 13/157 (8.3) 6/61 (9.8) 19/218 (8.7) 4/157 (2.5) 1/61 (1.6) 5/218 (2.3)
Asia/Pacific Rim 152/689 (22.1) 42/296 (14.2) 194/985 (19.7) 198/689 (28.7) 98/296 (33.1) 296/985 (30.1) 192/688 (27.9) 83/302 (27.5) 275/990 (27.8) 23/688 (3.3) 12/302 (4.0) 35/990 (3.5)
Europe 536/2786 (19.2) 559/2983 (18.7) 1095/5769 (19.0) 295/2786 (10.6) 302/2983 (10.1) 597/5769 (10.3) 436/3011 (14.5) 499/3311 (15.1) 935/6322 (14.8) 56/3011 (1.9) 45/3311 (1.3) 101/6322 (1.6)
Latin America 226/771 (29.3) 139/397 (35.0) 365/1168 (31.3) 105/771 (13.6) 60/397 (15.1) 165/1168 (14.1) 154/747 (20.6) 84/410 (20.5) 238/1157 (20.6) 8/747 (1.1) 12/410 (2.9) 20/1157 (1.7)
Middle East 54/182 (29.7) 87/278 (31.3) 141/460 (30.7) 43/182 (23.6) 70/278 (25.2) 113/460 (24.6) 42/210 (20.0) 53/281 (18.9) 95/491 (19.3) 1/210 (0.5) 4/281 (1.4) 5/491 (1.0)
North America 1180/4280 (27.6) 316/1555 (20.3) 1496/5835 (25.6) 646/4280 (15.1) 254/1555 (16.3) 900/5835 (15.4) 1015/3919 (25.9) 410/1673 (24.5) 1425/5592 (25.5) 40/3919 (1.0) 22/1673 (1.3) 62/5592 (1.1)
Global 2215/8864 (25.0) 1159/5574 (20.8) 3374/14438 (23.4) 1327/8864 (15.0) 805/5574 (14.4) 2132/14438 (14.8) 1852/8732 (21.2) 1135/6038 (18.8) 2987/14770 (20.2) 132/8732 (1.5) 96/6038 (1.6) 228/14770 (1.5)
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(54.8%) (Table 2). β-lactamase production was reported
among 2987 (20.2%) of isolates while 228 (1.5%) isolates
were BLNAR (Table 3). H. influenzae was highly suscep-
tible (>98%) to most of the agents on the T.E.S.T. panel;
the exception to this was ampicillin, for which suscepti-
bility ranged from 68.7% in Asia/Pacific Rim to 89.0% in
Africa. Globally, there was very little change in H. in-
fluenzae antimicrobial susceptibility between 2004-2008
and 2009-2012 (Additional file 1: Table S2). The most
common isolate sources were respiratory (71.1%) and
head, ears, eyes, nose and throat (18.4%) (Table 2).
The global prevalence of β-lactamase-positive H. in-
fluenzae decreased significantly (p < 0.001) during this
study, from 21.2% (95% CI 20.4-22.1) in 2004-2008 to
18.8% (95% CI 17.8-19.8) in 2009-2012 (Table 3). The
prevalence of β-lactamase-positive H. influenzae was
highest in Asia/Pacific Rim (27.8%) and North America
(25.5%) (Table 3). With the exception of ampicillin (to
which β-lactamase-positive isolates are resistant), sus-
ceptibility among β-lactamase-positive isolates was stable
between 2004-2008 and 2009-2012 (Additional file 1:
Table S2).
BLNAR isolates were collected from all regions glo-
bally and were least common in Middle East (1.0%) and
North America (1.1%); prevalence was highest in Asia/
Pacific Rim (3.5%). The global incidence of BLNAR
remained consistent during this study, at 1.5% in 2004-
2008 and 1.6% in 2009-2012 (Table 3). Antimicrobial
susceptibility also did not change over the study period
(Additional file 1: Table S2).
Discussion
This report shows that S. pneumoniae global suscepti-
bility has remained relatively stable to most antimicro-
bial agents globally during the period 2004 to 2012. This
reflects the findings of the European Antimicrobial Re-
sistance Surveillance Network (EARS-Net), who showed
that non-susceptibility among invasive S. pneumoniae in
Europe has remained stable between 2004 and 2011,
although large variations existed between countries [1].
Results from the SENTRY study in the USA between
1998 and 2011 showed increased resistance among
S. pneumoniae to amoxicillin-clavulanate, penicillin (at
MIC ≥4 mg/L) and ceftriaxone (18.9%, 14.8% and 11.7%,
respectively), although levofloxacin, linezolid, tigecycline
and vancomycin retained 100% activity [16]. Differences
between this study and that of Jones et al. [16] may be
attributed to the different time period of isolate collec-
tion (SENTRY commenced in 1998 compared with the
start of TEST in 2004) as well as the source of isolate
collection. Also, geography may influence the findings as
the current study is a global collection of isolates com-
pared with the USA analysis of Jones et al. [16]. Thechange in the CLSI breakpoints for S. pneumoniae and
penicillin in 2008 also mean that caution must be exer-
cised when comparing susceptibility data between stud-
ies [17]. The Jones et al. [16] study used an MIC of
≥4 mg/L for penicillin resistance whereas in this T.E.S.T.
study we have used the CLSI penicillin oral breakpoints
where resistance is defined as an MIC of ≥2 mg/L.
Susceptibility to ceftriaxone and minocycline among
S. pneumoniae isolates decreased in all the regions;
although in the case of ceftriaxone rates of susceptibility
remained high. Reasons for these decreases are unknown
and warrant further investigation. One factor that may
influence susceptibility among S. pneumoniae is the use
of the seven- and 13-valent pneumococcal conjugate
vaccines (PCV7 and PCV13) which have been shown to
modify the epidemiology of pneumococcal disease [18].
The S. pneumoniae collected as part of T.E.S.T. which
have elevated ceftriaxone and minocycline MICs warrant
molecular analysis to investigate the influence of these
vaccines on the resistance profile of S. pneumoniae
globally.
The high levels of susceptibility to tigecycline among
S. pneumoniae and H. influenzae reported in the current
study mirror recent results presented elsewhere. The
Assessing Worldwide Antimicrobial Resistance Evaluation
Program (AWARE) reported 100% tigecycline suscepti-
bility among Latin American S. pneumoniae isolates from
respiratory tract or complicated skin and soft tissue infec-
tions [19]; Zhao et al. reported no tigecycline resistance
among 5608 Gram-positive isolates collected in China bet-
ween 2005 and 2010 [20]; Jones et al. observed 100% tige-
cycline susceptibility among S pneumoniae isolates in the
USA between 1998 and 2011 [16]; and Nilsson et al. ob-
served good tigecycline activity against S. pneumoniae iso-
lates from Northern European countries with a MIC90 of
0.125 mg/L [21]. Nilsson et al. also reported a low MIC90
(0.25 mg/L) for tigecycline against H. influenzae.
The tigecycline susceptibility results presented here for
S. pneumoniae are different from those presented by
Darabi et al. [12] in their discussion of S. pneumoniae
collected globally between 2004 and 2008 as a part of
the T.E.S.T. study. In the earlier report, S. pneumoniae
susceptibility to tigecycline ranged from 87.5% in Latin
America to 97.1% in the Middle East; in the current re-
port, tigecycline susceptibility was ≥99.8% in all global
regions. These changes are likely due to the MIC re-
testing of several hundred reportedly tigecycline non-
susceptible pneumococci since the publication of Darabi
et al. [12]. Re-testing occurred because of the determin-
ation that lysed sheep blood in the testing media results
in artificially high tigecycline MICs. The re-testing pro-
gram is carried out by the central laboratory, IHMA,
who use un-lysed sheep blood to retest all S. pneumo-
niae. This program began with the retesting of the most
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isolates received and therefore, some early S. pneu-
moniae MIC results may have been published before all
retests were completed. To date, all S. pneumoniae with
a tigecycline MIC above 0.06 mg/L have retested at or
below 0.06 mg/L (data not shown). The difference in re-
sults may also be due to the deletion of unevaluable iso-
lates from the T.E.S.T. database. During the production
of the dataset used in this manuscript, 236 quarantined
S. pneumoniae isolates could not be re-evaluated for sus-
ceptibility (i.e., isolates which died on transport from
collecting centre to the central laboratory [IHMA], were
never shipped to IHMA, or could not be resuscitated for
retesting) and were thus permanently removed from the
T.E.S.T. database (S. Bouchillon, pers com).
As discussed above, in the current study, oral breakpoints
(susceptible ≤0.06 mg/L, resistant ≥2 mg/L) have been used
for penicillin against S. pneumoniae and not the parenteral
breakpoints (meningitis: susceptible ≤0.06 mg/L, resis-
tant ≥0.12 mg/L; non-meningitis: susceptible ≤2 mg/L,
resistant ≥8 mg/L). Use of these oral breakpoints in the
current study suggests that penicillin resistance is high
globally (PISP, 23.4%; PRSP, 14.8%), thus oral penicillin
treatment of pneumonia caused by S. pneumoniae
would appear to be ill-advised. However, the occurrence
of S. pneumoniae isolates with MICs ≥4 mg/L is rare
worldwide [22], and the use of high-dose parenteral
penicillin is generally effective in the treatment of pneu-
monia caused by drug-resistant S. pneumoniae [23].
H. influenzae isolates were highly susceptible to most
agents on the T.E.S.T. panel, with global susceptibility
ranging from 98.8% (tigecycline) to 99.9% (ceftriaxone,
levofloxacin, imipenem and meropenem) during the
2004-2012 interval; the sole exception was ampicillin, to
which only 78.3% of isolates were susceptible globally.
Regionally, susceptibility in Europe (83.6%) was higher
than in North America (73.4%). These regional results
compare well with Jones et al., who reported 85.2% and
71.7% ampicillin susceptibility among H. influenzae iso-
lates from Europe and the USA, respectively [24]. Global
BLNAR levels were low (1.5%) in the current study.
Japan is known to have a relatively high prevalence of
BLNAR H. influenzae [25]; however, no Japanese sites
contributed isolates to this study. The USA and Europe,
where the majority of T.E.S.T. isolates were collected
have lower rates but rates have been reported to be in-
creasing in Europe [26,27]. Studies contemporary with
this T.E.S.T. study are scarce making direct comparisons
of percentages difficult; however, continued monitoring
of these isolates is important, particularly given reports
of increasing prevalence.
In the first three years of the T.E.S.T. study, contribu-
ting centres in North America were two- to three-fold
more numerous than centres from Europe. Since 2008,however, European centres have outnumbered those in
North America. This is reflected in the numbers of iso-
lates contributed from these two regions: between 2004
and 2008, 48.3% of S. pneumoniae and 44.9% of H. in-
fluenzae isolates were contributed by centres in North
America compared to 31.4% and 34.5%, respectively, by
centres in Europe. When the total study period (2004-
2012) is considered, S. pneumoniae is contributed
equally from both regions (40.4% from North America
compared to 40.0% from Europe); H. influenzae isolates
from Europe (42.8%), however, outnumbered those from
North America (37.9%). This shift in prevalence from
North America to Europe will undoubtedly have influ-
enced overall susceptibility rates observed over the
course of this study, as susceptibility was lower in North
America than in Europe for most antimicrobial agents
between 2004 and 2012. The number of isolates submit-
ted from the other four regions was similar between the
two time periods, contributing approximately 19% of
isolates. The change in the number of North American
and European centres over time reinforces the im-
portance of presentation of regional data from global
surveillance studies, where possible. This inconsistency
in participating centres over time is an inherent weak-
ness of longitudinal surveillance studies, especially in-
ternational or global surveillance studies. Thus, as is
always the case with data derived from multicentre lon-
gitudinal surveillance, the trends in antimicrobial sus-
ceptibility reported here must be regarded with some
caution.
Conclusions
S. pneumoniae remained highly susceptible to levo-
floxacin, linezolid, tigecycline and vancomycin while
H. influenzae was susceptible to most antimicrobial
agents in the T.E.S.T. panel (excluding ampicillin). Tige-
cycline was approved for the treatment of community-
acquired bacterial pneumonia in the USA by the FDA in
2009. The results presented in this report show that the
in vitro susceptibility of S. pneumoniae and H. influen-
zae, two important pathogens which are commonly as-
sociated with community-associated pneumonia, has
remained high globally in the period since this approval
was granted. Tigecycline may thus continue to be an
important tool in the armamentarium of physicians for
the treatment of CABP.Additional file
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